Social Media Ideas for Novartis

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

<![CDATA[Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials]]>

Novartis gains expanded indication for Pluvicto

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta]]>

Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the techn...

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of...

Novartis telegraphs 130 job cuts amid biologics rethink in Switzerland

Novartis could cut about 130 jobs in Switzerland as it rethinks its biologics technical development and production footprint in Basel.

Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal

For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan expla...

<![CDATA[Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report ]]>

Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore

The development comes after private-equity firm ChrysCapital’s acquisition of the entire 70.68 per cent stake in Novartis India Ltd

<![CDATA[M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with...

<![CDATA[Simcere Zaiming Licenses Sim0660 to Roche for $1.53 billion]]>

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor lande...

Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says

The Swiss drugmaker reported earnings a few days ago and, so far, has done a good job holding near its recent highs.

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Is Novartis the worst of the worst within big pharma?

Is Novartis the worst of the worst within big pharma? Anonymous (not verified) Fri, 08/28/2026 - 09:41 field_thread_url https://cafepharma.com/boards/threa...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Novartis India Ltd gets recast as ChrysCapital acquires Swiss parent’s stake

The ₹1,446-crore deal follows Novartis AG’s strategic review, with the listed entity NIL set to adopt a new identity under ChrysCapital’s ownership

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>